Francis Richard D 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 5, 2026
Insider Transaction Report
Form 4
Francis Richard D
President and CEO
Transactions
- Exercise/Conversion
Ordinary Shares
[F1][F2]2026-03-03+67,231→ 673,002 total - Sale
Ordinary Shares
[F1][F3][F4][F5]2026-03-03$32.36/sh−30,903$1,000,018→ 642,099 total - Exercise/Conversion
Ordinary Shares
[F1][F2]2026-03-03+891,315→ 1,533,414 total - Sale
Ordinary Shares
[F1][F3][F4][F5]2026-03-03$32.36/sh−412,032$13,333,314→ 1,121,382 total - Exercise/Conversion
Restricted Share Units
[F2][F6][F1]2026-03-03−67,231→ 67,231 total→ Ordinary Shares (67,231 underlying) - Exercise/Conversion
Restricted Share Units
[F2][F7][F1]2026-03-03−891,315→ 0 total→ Ordinary Shares (891,315 underlying)
Footnotes (7)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.
- [F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.865, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F6]Restricted share units were granted on March 3, 2023, with 67,231 vested on each of March 3, 2024, March 3, 2025 and March 3, 2026, and 67,231 vesting on March 3, 2027.
- [F7]Restricted share units were earned on January 27, 2026, as a result of the satisfaction of certain performance criteria certified by the Human Resources and Compensation Committee and subsequently vested on March 3, 2026, following satisfaction of the time-based vesting criteria.
Signature
/s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis|2026-03-05